Lebrikizumab treatment in adults with asthma.

  title={Lebrikizumab treatment in adults with asthma.},
  author={Jonathan Corren and Robert F. Lemanske and Nicola Alexander Hanania and Phillip E. Korenblat and Merdad V Parsey and Joseph R Arron and Jeffrey M. Harris and Heleen Scheerens and Lawren C. Wu and Zheng Su and Sofia Mosesova and Mark David Eisner and Sean P Bohen and John G Matthews},
  journal={The New England journal of medicine},
  volume={365 12},
BACKGROUND Many patients with asthma have uncontrolled disease despite treatment with inhaled glucocorticoids. One potential cause of the variability in response to treatment is heterogeneity in the role of interleukin-13 expression in the clinical asthma phenotype. We hypothesized that anti-interleukin-13 therapy would benefit patients with asthma who had a pretreatment profile consistent with interleukin-13 activity. METHODS We conducted a randomized, double-blind, placebo-controlled study… CONTINUE READING